Lisata Therapeutics Achieves Recognition in Biotechnology
Lisata Therapeutics, Inc. (NASDAQ: LSTA) has recently earned a prestigious accolade as the 'Specialized BioTherapeutics Company of the Year' in the notable BioTech Breakthrough Awards program. This annual award showcases excellence in life sciences and biotechnology, serving as a testament to Lisata's commitment to innovation in addressing the challenges faced by patients with advanced solid tumors.
A Mission-Driven Approach to Therapeutics
The BioTech Breakthrough Award highlights Lisata Therapeutics' dedication to developing pioneering therapies aimed at unmet medical needs. Utilizing the proprietary CendR Platform® technology, Lisata has created novel methods for delivering anti-cancer drugs more effectively. This technology aims to enhance the potency of established treatments and emerging therapies, including cytotoxics and immunotherapies.
Certepetide: A Promising Investigational Drug
One of Lisata's leading investigational therapies, certepetide, is designed to transform the tumor microenvironment by reducing its immunosuppressive characteristics. The treatment encourages the recruitment of cytotoxic T cells, critical components in the body's immune defense, while inhibiting the spread of cancer. Certepetide has shown promising results in early trials, particularly for pancreatic cancer and has received special designations from the U.S. Food and Drug Administration (FDA) that could expedite its development.
Industry Recognition and Future Directions
David J. Mazzo, Ph.D., President and CEO of Lisata, emphasized that this recognition reflects the hard work of the entire Lisata team and their collaborators. With ongoing evaluations and trials, the company is focused on expanding its therapeutic portfolio to deliver impactful treatments to patients.
Expanding the Reach of Certepetide
The innovative work surrounding certepetide extends beyond oncology. Lisata is exploring the potential of this treatment for non-oncologic conditions, such as endometriosis, demonstrating their commitment to addressing critical healthcare needs on various fronts. Bryan Vaughn, Managing Director of BioTech Breakthrough, mentioned that Lisata is making strides in transforming patient lives through its scientific discoveries and therapeutic advances.
Global Impact and Community Engagement
Each year, the BioTech Breakthrough Awards attract numerous nominations across various life science categories from a multitude of countries. This international recognition not only promotes technological advancement but also encourages new ideas that shape the future of biotechnology.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of therapies for serious diseases, particularly advanced solid tumors. The company's unique iRGD cyclic peptide product candidate, certepetide, is at the forefront of its innovative approach, targeting and effectively treating challenging cancers.
Contact Information
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
Frequently Asked Questions
What is the BioTech Breakthrough Award?
The BioTech Breakthrough Award recognizes leading companies and products in the biotech sector, honoring excellence in innovation and impact on the industry.
What is certepetide?
Certepetide is an investigational drug by Lisata Therapeutics aimed at enhancing the delivery of anti-cancer agents to tumors and modifying the tumor microenvironment.
Why was Lisata Therapeutics recognized?
Lisata was recognized for its innovative approaches to treating advanced solid tumors and its commitment to developing novel therapies to meet unmet medical needs.
What are Lisata's plans for future research?
Lisata Therapeutics plans to continue advancing its clinical trials and exploring the potential of certepetide in various medical applications beyond oncology.
How can I stay updated on Lisata's developments?
You can stay updated on Lisata's progress through their official website and by following their press releases for the latest announcements in their research and product development.
